Oncology News | pharmaphorum

News

AI drug R&D company Exscientia signs deal with Celgene

UK artificial intelligence (AI) drug discovery company Exscientia has agreed a three year drug discovery deal with Celgene, focusing on finding new cancer and autoimmune drugs.

News

Question marks over AbbVie/Roche's venetoclax after safety s...

AbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a higher proportion of deaths was observed in patients receiving it tha

News

Roche's Tecentriq gains new US lung cancer indication

Roche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it a licence in a difficult to treat form of lung cancer in combination wi

News

Celgene gets US patent let-off ahead of BMS merger

Shares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on its multi-billion dollar cancer drug Revlimid, a decision that could ease shareholder ten

News

Keytruda bags another EU approval in frontline lung cancer

Merck & Co/MSD has tightened its hold on the first-line lung cancer market with another EU approval for Keytruda – this time for its use alongside chemotherapy in patients with metastat

News

UK gets early access to Roche’s breast cancer immunotherapy

Hard on the heels of an FDA approval for Roche’s Tecentriq and Celgene’s Abraxane for triple-n

AI drug R&D company Exscientia signs deal with Celgene

Question marks over AbbVie/Roche's venetoclax after safety s...

Roche's Tecentriq gains new US lung cancer indication

Celgene gets US patent let-off ahead of BMS merger

Keytruda bags another EU approval in frontline lung cancer

UK gets early access to Roche’s breast cancer immunotherapy

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks